Alnylam Pharmaceuticals, Inc. (ALNY) Financials
ALNY Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 3.8 billion | 4.1 billion |
2023-09-30 | 3.8 billion | 4.0 billion |
2023-06-30 | 3.4 billion | 3.8 billion |
2023-03-31 | 3.4 billion | 3.7 billion |
ALNY Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -45.1 million | 42.0 million |
2023-09-30 | 342.3 million | 63.9 million |
2023-06-30 | -74.9 million | 75.8 million |
2023-03-31 | -180.4 million | 39.9 million |
ALNY Net Income
No data available :(
ALNY Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 2.4 billion | - | 284.6 million |
2023-09-30 | 2.4 billion | - | 289.2 million |
2023-06-30 | 2.1 billion | 1.0 billion | 295.5 million |
2023-03-31 | 2.1 billion | 1.0 billion | 302.5 million |
ALNY Shares Outstanding
ALNY Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 15.3 million | 272.1 million | 198.1 million | - |
2023-09-30 | 17.1 million | 253.2 million | 199.2 million | - |
2023-06-30 | 15.9 million | 248.5 million | 214.7 million | - |
2023-03-31 | 13.9 million | 230.6 million | 183.7 million | - |
ALNY Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 439.7 million | 85.9 million |
2023-09-30 | 750.5 million | 84.3 million |
2023-06-30 | 318.8 million | 85.4 million |
2023-03-31 | 319.3 million | 54.9 million |
ALNY
Price: $152.33
52 week price:
Earnings Per Share: -3.52 USD
P/E Ratio: -41.14
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 712302
Ebitda: -143.6 millionMarket Capitalization: 19.2 billion